Related Experiment Video
Updated: May 30, 2026
Synergizing Antegrade Endoscopic with Bridging Vein Harvesting for Improvement of Great Saphenous Vein Graft Quality from the Lower Leg
Published on: November 19, 2019
Saphenous vein graft intervention
Michael S Lee1, Seung-Jung Park, David E Kandzari
1University of California-Los Angeles Medical Center, Los Angeles, California, USA. mslee@mednet.ucla.edu
Insights
Saphenous vein graft interventions have poor outcomes, but embolic protection devices and drug-eluting stents may improve results. Further research is needed to compare stent types for these high-risk patients.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Vascular Surgery
Background:
- Saphenous vein grafts (SVGs) are crucial for coronary artery bypass grafting but have limited long-term patency.
- Percutaneous revascularization of SVGs carries higher risks of adverse events than native coronary interventions.
- Embolic protection devices (EPDs) are recommended but underutilized for SVG interventions.
Purpose of the Study:
- To review the challenges and current strategies for percutaneous revascularization of saphenous vein grafts.
- To evaluate the efficacy of embolic protection devices and pharmacological agents in mitigating procedural risks.
- To assess the role of different stent types, particularly drug-eluting stents, in improving outcomes for SVG interventions.
Main Methods:
- Review of current literature and clinical guidelines regarding SVG interventions.
- Analysis of outcomes associated with percutaneous coronary intervention in SVGs versus native coronary arteries.
- Evaluation of evidence for embolic protection devices, pharmacological therapies, and stent types (covered, bare-metal, drug-eluting).
Main Results:
- SVG interventions are linked to worse clinical outcomes, including restenosis, myocardial infarction, and death.
- Embolic protection devices are underused despite guideline recommendations for reducing distal embolization and no-reflow.
- Drug-eluting stents show promise in reducing restenosis, but further randomized trials are needed to compare them with bare-metal stents.
Conclusions:
- Percutaneous treatment of SVGs presents significant challenges with suboptimal long-term results.
- Optimizing procedural techniques with EPDs and appropriate pharmacological support is crucial.
- Drug-eluting stents are favored for reducing restenosis in SVGs, pending further comparative evidence from large trials.
Abstract:
Saphenous vein grafts are commonly used conduits for surgical revascularization of coronary arteries but are associated with poor long-term patency rates. Percutaneous revascularization of saphenous vein grafts is associated with worse clinical outcomes including higher rates of in-stent restenosis, target vessel revascularization, myocardial infarction, and death compared with percutaneous coronary intervention of native coronary arteries. Use of embolic protection devices is a Class I indication according to the American College of Cardiology/American Heart Association guidelines to decrease the risk of distal embolization, no-reflow, and periprocedural myocardial infarction. Nonetheless, these devices are underused in clinical practice. Various pharmacological agents are available that may also reduce the risk of or mitigate the consequences of no-reflow. Covered stents do not decrease the rates of periprocedural myocardial infarction and restenosis. Most available evidence supports treatment with drug-eluting stents in this high-risk lesion subset to reduce angiographic and clinical restenosis, although large, randomized trials comparing drug-eluting stents and bare-metal stents are needed.
Related Concept Videos
01:23Peripheral Artery Disease V: Postoperative Nursing Management
01:26Varicose Veins II: Diagnostic Studies and Interprofessional Care
01:25Hemodialysis I: Introduction